NeuroScientific Biopharmaceuticals Limited (ASX:NSB)

ASX:NSB Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Other Revenue	2.21	2.21	4.95	-	0.96	-
Revenue	2.21	2.21	4.95	-	0.96	-
Revenue Growth (YoY)	-41.71%	-55.34%	-	-	-	-
Cost of Revenue	0.02	0.02	0.05	0.07	0.04	0.03
Gross Profit	2.19	2.19	4.91	-0.07	0.92	-0.03
Selling, General & Admin	0.83	1.36	1.75	1.8	1.28	0.93
Research & Development	0.27	0.49	4.03	7.22	2.22	1.42
Operating Expenses	1.18	2.03	6.08	10.44	4.18	2.91
Operating Income	1.01	0.16	-1.17	-10.5	-3.26	-2.94
Interest Expense	-0	-0.01	-0	-	-0	-0
Interest & Investment Income	0.18	0.18	0.11	0.07	0.03	0.04
Other Non Operating Income (Expenses)	-	-	-	-	0	-
EBT Excluding Unusual Items	1.19	0.32	-1.07	-10.44	-3.24	-2.91
Other Unusual Items	-	-	-	-	0.06	0.04
Pretax Income	1.19	0.32	-1.07	-10.44	-3.18	-2.87
Net Income	1.19	0.32	-1.07	-10.44	-3.18	-2.87
Net Income to Common	1.19	0.32	-1.07	-10.44	-3.18	-2.87
Shares Outstanding (Basic)	146	145	143	143	143	78
Shares Outstanding (Diluted)	146	145	143	143	143	78
Shares Change (YoY)	1.15%	0.72%	-	-	83.04%	9.59%
EPS (Basic)	0.01	0.00	-0.01	-0.07	-0.02	-0.04
EPS (Diluted)	0.01	0.00	-0.01	-0.07	-0.02	-0.04
Free Cash Flow	1.16	0.04	-2.3	-6.95	-2.63	-2.28
Free Cash Flow Per Share	0.01	-	-0.02	-0.05	-0.02	-0.03
Gross Margin	98.98%	98.90%	99.07%	-	95.87%	-
Operating Margin	45.50%	7.02%	-23.65%	-	-340.53%	-
Profit Margin	53.66%	14.66%	-21.57%	-	-331.45%	-
Free Cash Flow Margin	52.30%	1.92%	-46.52%	-	-274.46%	-
EBITDA	1.1	0.25	-1.11	-10.44	-3.2	-2.88
EBITDA Margin	49.77%	11.15%	-22.48%	-	-	-
D&A For EBITDA	0.09	0.09	0.06	0.06	0.06	0.06
EBIT	1.01	0.16	-1.17	-10.5	-3.26	-2.94
EBIT Margin	45.50%	7.02%	-23.65%	-	-	-

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.